



Press release
Gothenburg, Sweden
January 25, 2021, 14:00 CET

CELLINK launches UP.SIGHT, a rapid, all-in-one imager and single-cell dispenser that offers double assurance of clonality

UP.SIGHT™ is certified to help laboratories worldwide overcome major cell line development hurdles and improve efficiency across workflows.

cytена GmbH, a CELLINK company and leader in single cell dispensing technologies, launches the UP.SIGHT, a transformative single-cell dispensing system that increases efficiency in cell line development workflows. This all-in-one solution is equipped with cytена's patented, fast and gentle single-cell dispensing technology and a rapid, high-quality imaging system that enables nozzle imaging and 3D Full Well Imaging (with no need for image stitching). It offers double assurance of clonality from two independent optical apparatuses and leads to a probability of clonality >99.99%.

"The UP.SIGHT represents a significant improvement in single-cell dispensing and the cell line development workflow," says Erik Gatenholm, CEO of CELLINK. "Until now, the pharmaceutical industry has used a costly, time-consuming and wasteful process when isolating single cells for research purposes. Compared to existing single-cell dispensers, the UP.SIGHT is faster, more efficient and does it all in one device, while they require multiple devices. The UP.SIGHT is an example of the CELLINK Group's commitment to bio-convergence and finding synergies in biology and engineering to create truly innovative technologies."

Today, 8 out of the top 10 best-selling drugs worldwide are developed using biologics, and cell line development is an essential component of their production. The UP.SIGHT is the next generation of cytена's single-cell dispensers and with high-precision cell deposition and imaging to ensure precise cell isolation and monoclonality. The UP.SIGHT streamlines cell line development so researchers can work faster and smarter. Additionally, cytена's EASY.ON disposable cartridges eliminate the risk of cross-contamination and the need for extensive cleaning processes.

For further information, please contact:

Erik Gatenholm, CEO

Phone (Sweden): +46 73 267 00 00
Phone (US): +1 (650) 515 5566
Email: eg@cellink.com

Gusten Danielsson, CFO

Phone (Sweden): +46 70 991 86 04
Phone (US): +1 (857) 332 2138
Email: gd@cellink.com

This information was submitted for publication, through the agency of the contact persons set out above, on January 25, 2021, at 14:00. (CET).

About CELLINK

Founded in 2016, CELLINK is the leading bioconvergence company in world that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries. CELLINK's products are trusted by more than 1,800 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 65+ countries, and have been cited in more than 700 publications. CELLINK is creating the future of medicine.

Visit cellink.com to learn more. CELLINK is listed on the Nasdaq Stockholm under CLNK B.